Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Antiviral therapy and hepatitis B virus-related hepatocellular carcinoma recurrence--reply.

Wu CY, Hsu YC.

JAMA. 2013 Feb 27;309(8):766-7. doi: 10.1001/jama.2013.574. No abstract available.

PMID:
23443431
2.

Antiviral therapy and hepatitis B virus-related hepatocellular carcinoma recurrence.

Yeh YC, Chen PJ, Lai MS.

JAMA. 2013 Feb 27;309(8):765-6. doi: 10.1001/jama.2013.571. No abstract available.

PMID:
23443430
3.

Antiviral therapy and hepatitis B virus-related hepatocellular carcinoma recurrence.

Hsu CS.

JAMA. 2013 Feb 27;309(8):765. doi: 10.1001/jama.2013.568. No abstract available.

PMID:
23443429
4.
5.
6.

High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study.

Yang T, Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, Shen F, Wu MC.

Eur J Surg Oncol. 2012 Aug;38(8):683-91. doi: 10.1016/j.ejso.2012.04.010. Epub 2012 May 22.

PMID:
22621971
7.

Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.

Chung GE, Kim W, Lee JH, Kim YJ, Yoon JH, Lee JM, Lee JY, Kim SH, Kim D, Lee HS.

J Gastroenterol Hepatol. 2011 Nov;26(11):1638-45. doi: 10.1111/j.1440-1746.2011.06777.x.

PMID:
22011297
8.

Recent advances in the prevention of hepatocellular carcinoma recurrence.

Lu LC, Cheng AL, Poon RT.

Semin Liver Dis. 2014 Nov;34(4):427-34. doi: 10.1055/s-0034-1394141. Epub 2014 Nov 4. Review.

PMID:
25369304
9.
10.

Hepatitis B virus DNA and hepatocellular carcinoma recurrence after resection: the lower, the better!

You H, Jia JD.

J Gastroenterol Hepatol. 2010 Dec;25(12):1812-4. doi: 10.1111/j.1440-1746.2010.06516.x. No abstract available.

PMID:
21091989
11.

Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma.

Llovet JM, Lok A.

J Natl Cancer Inst. 2008 Aug 20;100(16):1121-3. doi: 10.1093/jnci/djn261. Epub 2008 Aug 11. No abstract available.

12.

A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection.

Li N, Lai EC, Shi J, Guo WX, Xue J, Huang B, Lau WY, Wu MC, Cheng SQ.

Ann Surg Oncol. 2010 Jan;17(1):179-85. doi: 10.1245/s10434-009-0694-z. Epub 2009 Aug 29.

PMID:
19727956
13.

How does hepatitis B virus infection react to hepatocellular carcinoma treatment?

Wong GL.

J Gastroenterol Hepatol. 2012 Jan;27(1):1-2. doi: 10.1111/j.1440-1746.2011.06950.x. No abstract available.

PMID:
22188022
14.

The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma.

Chuma M, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, Yamamoto Y, Nakanishi M, Kohara T, Sho T, Yamamoto K, Horimoto H, Kobayashi T, Yokoo H, Matsushita M, Todo S, Asaka M.

J Gastroenterol. 2009;44(9):991-9. doi: 10.1007/s00535-009-0093-z. Epub 2009 Jun 25.

PMID:
19554391
15.

Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding Milano criteria in a patient with hepatitis B virus cirrhosis: a case report.

Nakamura Y, Hama K, Iwamoto H, Yokoyama T, Kihara Y, Konno O, Jojima Y, Shimazu M.

Transplant Proc. 2012 Mar;44(2):565-9. doi: 10.1016/j.transproceed.2012.01.029.

PMID:
22410070
16.

[Ratio analysis of HBV-related liver disease and primary liver carcinoma development over 10 years in patients who received no antiviral therapy versus those treated with antiviral therapy].

Huo H, Ren S, Wang S, Xu Y, Ma L, Liu Y, Jin Y, Zheng Y, Chen X.

Zhonghua Gan Zang Bing Za Zhi. 2014 Jan;22(1):68-70. Chinese. No abstract available.

PMID:
24754089
17.

Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.

Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C, Samuel D.

Gastroenterology. 2008 Jun;134(7):1890-9; quiz 2155. doi: 10.1053/j.gastro.2008.02.064. Epub 2008 Mar 4.

PMID:
18424269
18.

Preventing infection-associated cancer: from bench to hillside.

Goedert JJ.

J Natl Cancer Inst. 2005 Feb 16;97(4):245-6. No abstract available.

19.

Quiet reflection after effective action: hepatitis B viraemia and hepatocellular carcinoma recurrence.

Abdo AA, Sanai FM.

Liver Int. 2008 Apr;28(4):423-5. doi: 10.1111/j.1478-3231.2008.01731.x. No abstract available.

PMID:
18339067
20.

Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma.

Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D, Guo R, Chen M, Li S, Lin X, Yuan Y.

Liver Int. 2013 Apr;33(4):595-604. doi: 10.1111/liv.12112. Epub 2013 Feb 13.

PMID:
23402625
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk